Long-Term Data for Kite's Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

Related Keywords

Foster City ,California ,United States ,New York ,Canada ,Anaheim ,North Vancouver ,British Columbia ,American ,Canadian ,Frank Neumann ,Meaghan Smith ,Anna Padula ,Jerome Powell ,Barbara Shecter ,Gabriel Friedman ,Santa Monica ,Julioc Chavez ,Joe Oconnor ,Jacquie Ross ,Gilead Company ,Federal Reserve ,Linkedin ,International Prognostic Index ,Gilead Company Nasdaq ,Postmedia Network Inc ,Kite Global Head Of Clinical Development ,Exchange Commission ,Gilead Sciences ,Gilead Sciences Inc ,American Society Of Hematology ,Moffitt Cancer Center ,National Post ,Business Wire ,Term Data ,Cell Therapy Presented ,High Rate ,Durable Response ,Patients With High Risk Largeb Cell ,First Ever Prospective Phase ,Cell Therapy ,Patients Treated ,Complete Response Rate ,Three Year Estimate ,Overall Survival ,High Risk Largeb Cell Lymphoma ,Patients Typically Face Poor Prognoses ,Conventional Treatment ,Median Overall Survival Under ,American Society ,Annual Meeting ,Joeo Connor ,Victoria Wells ,Financial Times ,Financial Post ,New York Times ,Moffitt Cancer ,Confidence Interval ,Global Head ,Lugano Classification ,Postmedia Network ,Top Stories ,Release Syndrome ,Risk Evaluation ,Mitigation Strategy ,Private Securities Litigation Reform Act ,Quarterly Report ,Gilead Media ,Kite Media ,Angeles Angel Shohei Ohtani ,Detroit Tigers ,